Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126548031 | 12654803 | 1 | I | 20160802 | 20160816 | 20160816 | EXP | 000628656 | CA-CONCORDIA PHARMACEUTICALS INC.-CO-KX-CA-2016-019 | CONCORDIA | 62.00 | YR | F | Y | 0.00000 | 20160815 | OT | CA | CA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126548031 | 12654803 | 1 | PS | KAYEXALATE | SODIUM POLYSTYRENE SULFONATE | 1 | UNKNOWN | U | 0 | ||||||||||
| 126548031 | 12654803 | 2 | SS | KAYEXALATE | SODIUM POLYSTYRENE SULFONATE | 1 | U | 0 | |||||||||||
| 126548031 | 12654803 | 3 | SS | SOLIRIS | ECULIZUMAB | 1 | Intravenous (not otherwise specified) | 0 | 1200 | MG | |||||||||
| 126548031 | 12654803 | 4 | SS | SOLIRIS | ECULIZUMAB | 1 | Intravenous (not otherwise specified) | 0 | 900 | MG | |||||||||
| 126548031 | 12654803 | 5 | SS | SOLIRIS | ECULIZUMAB | 1 | Intravenous (not otherwise specified) | 0 | 900 | MG | /wk | ||||||||
| 126548031 | 12654803 | 6 | SS | SOLIRIS | ECULIZUMAB | 1 | Intravenous (not otherwise specified) | 0 | 900 | MG | /wk | ||||||||
| 126548031 | 12654803 | 7 | SS | SOLIRIS | ECULIZUMAB | 1 | Intravenous (not otherwise specified) | 0 | 1200 | MG | |||||||||
| 126548031 | 12654803 | 8 | SS | SOLIRIS | ECULIZUMAB | 1 | Intravenous (not otherwise specified) | 0 | 1200 | MG | |||||||||
| 126548031 | 12654803 | 9 | C | ADVAGRAF | TACROLIMUS | 1 | 0 | ||||||||||||
| 126548031 | 12654803 | 10 | C | APO-SALVENT | ALBUTEROL | 1 | 0 | ||||||||||||
| 126548031 | 12654803 | 11 | C | ATORVASTATIN | ATORVASTATIN | 1 | 0 | ||||||||||||
| 126548031 | 12654803 | 12 | C | CARDURA | DOXAZOSIN MESYLATE | 1 | 0 | ||||||||||||
| 126548031 | 12654803 | 13 | C | DOCUSATE SODIUM. | DOCUSATE SODIUM | 1 | 0 | ||||||||||||
| 126548031 | 12654803 | 14 | C | FORZA-10 | 2 | 0 | |||||||||||||
| 126548031 | 12654803 | 15 | C | FUROSEMIDE. | FUROSEMIDE | 1 | 0 | ||||||||||||
| 126548031 | 12654803 | 16 | C | IRBESARTAN. | IRBESARTAN | 1 | 0 | ||||||||||||
| 126548031 | 12654803 | 17 | C | MAGNESIUM | MAGNESIUM | 1 | 0 | ||||||||||||
| 126548031 | 12654803 | 18 | C | NOVOGESIC | 2 | 0 | |||||||||||||
| 126548031 | 12654803 | 19 | C | PANTOPRAZOLE | PANTOPRAZOLE SODIUM | 1 | 0 | ||||||||||||
| 126548031 | 12654803 | 20 | C | SENNOSIDES. | SENNOSIDES | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126548031 | 12654803 | 1 | Hypertension |
| 126548031 | 12654803 | 3 | Glomerulonephritis membranoproliferative |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126548031 | 12654803 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126548031 | 12654803 | Back pain | |
| 126548031 | 12654803 | Blood creatinine increased | |
| 126548031 | 12654803 | Blood pressure increased | |
| 126548031 | 12654803 | Bronchitis | |
| 126548031 | 12654803 | Confusional state | |
| 126548031 | 12654803 | Cough | |
| 126548031 | 12654803 | Diarrhoea | |
| 126548031 | 12654803 | Diplopia | |
| 126548031 | 12654803 | Dizziness | |
| 126548031 | 12654803 | Dysarthria | |
| 126548031 | 12654803 | Dysgraphia | |
| 126548031 | 12654803 | Dysphagia | |
| 126548031 | 12654803 | Dysphonia | |
| 126548031 | 12654803 | Eye haemorrhage | |
| 126548031 | 12654803 | Gait disturbance | |
| 126548031 | 12654803 | Glomerular filtration rate decreased | |
| 126548031 | 12654803 | Headache | |
| 126548031 | 12654803 | Hypersensitivity | |
| 126548031 | 12654803 | Hypertension | |
| 126548031 | 12654803 | Hypoaesthesia | |
| 126548031 | 12654803 | Hypoaesthesia oral | |
| 126548031 | 12654803 | Migraine | |
| 126548031 | 12654803 | Oedema peripheral | |
| 126548031 | 12654803 | Off label use | |
| 126548031 | 12654803 | Oropharyngeal pain | |
| 126548031 | 12654803 | Pain in extremity | |
| 126548031 | 12654803 | Pharyngeal oedema | |
| 126548031 | 12654803 | Productive cough | |
| 126548031 | 12654803 | Pyrexia | |
| 126548031 | 12654803 | Rash erythematous | |
| 126548031 | 12654803 | Respiratory tract infection | |
| 126548031 | 12654803 | Road traffic accident | |
| 126548031 | 12654803 | Sputum discoloured | |
| 126548031 | 12654803 | Vision blurred | |
| 126548031 | 12654803 | Visual impairment |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |